Evidence map›Paper›PMID 40320464›Full record

ArticleScientific reports2025

hERG toxicity prediction in early drug discovery using extreme gradient boosting and isometric stratified ensemble mapping.

Gabriela Falcón-Cano, Aliuska Morales-Helguera, Heather Lambert, Miguel-Ángel Cabrera-Pérez, Christophe Molina

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriela Falcón-CanoPIKAÏROS, S.A, 31650, Saint Orens de Gameville, France.
Aliuska Morales-HelgueraPIKAÏROS, S.A, 31650, Saint Orens de Gameville, France.
Heather LambertPIKAÏROS, S.A, 31650, Saint Orens de Gameville, France.
Miguel-Ángel Cabrera-PérezDepartamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Angamos, 0610, Antofagasta, Chile.
Christophe MolinaPIKAÏROS, S.A, 31650, Saint Orens de Gameville, France. christophe.molina@pikairos.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blockade of the human Ether-à-go-go Related Gene (hERG) potassium channel by small molecules can prolong the QT interval, leading to fatal cardiotoxicity. Numerous drugs have been withdrawn from the market due to cardiac side effects, underscoring the need for early identification of hERG toxicity. Despite several classification machine learning (ML) models having been developed to this end, robustness, class imbalance, and interpretability are still challenges. Using the largest public database of hERG inhibition, this work integrates eXtreme Gradient Boosting (XGBoost) with Isometric Stratified Ensemble (ISE) mapping (XGB + ISE map) to enhance hERG prediction. An XGBoost consensus model was developed using balanced training sets and diverse variable subsets, resulting in robust models less affected by class imbalance. The model demonstrated competitive predictive performance, achieving a balance between sensitivity (SE = 0.83) and specificity (SP = 0.90) through exhaustive validation. ISE mapping estimated the model applicability domain and improved prediction confidence evaluation and compound selection by stratifying data. Refined variable selection procedures enhanced model interpretability. Variable importance analysis highlights key molecular determinants (peoe_VSA8, ESOL, SdssC, MaxssO, nRNR2, MATS1i, nRNHR, nRNH2) associated with hERG inhibition. The XGB + ISE map strategy provides an effective approach to identifying promising molecules in drug discovery campaigns with reduced hERG inhibition risk.

Indexed as

Drug DiscoveryERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsPotassium Channel BlockersCardiotoxicityHumansMachine LearningERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsPotassium Channel BlockersApplicability domainEnsemble methodsImbalanced datasetMachine learningVariable selection

Identifiers

PMID40320464
PMCPMC12050281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.